HIGHLIGHTS
- who: Rocco Capuano from the Department of Advanced Medical and Surgical Sciences (DAMSS), University of Campania "Luigi Vanvitelli", Naples, Italy have published the article: Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod, in the Journal: (JOURNAL) of March/31,/2022
- what: The authors investigated the effects of a third booster dose of BNT162b2 mRNA SARS-CoV-2 vaccine in pwMS treated with OCR and FNG in terms of: (i) qualitative and quantitative humoral response, comparing it to age . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.